Zimmermann Wolfram-Hubertus, Didié Michael, Döker Stephan, Melnychenko Ivan, Naito Hiroshi, Rogge Christina, Tiburcy Malte, Eschenhagen Thomas
Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
Cardiovasc Res. 2006 Aug 1;71(3):419-29. doi: 10.1016/j.cardiores.2006.03.023. Epub 2006 Apr 7.
Cardiac muscle engineering aims at providing functional myocardium to repair diseased hearts and model cardiac development, physiology, and disease in vitro. Several enabling technologies have been established over the past 10 years to create functional myocardium. Although none of the presently employed technologies yields a perfect match of natural heart muscle, it can be anticipated that human heart muscle equivalents will become available after fine tuning of currently established tissue engineering concepts. This review provides an update on the state of cardiac muscle engineering and its utilization in cardiac regeneration. We discuss the application of stem cells including the allocation of autologous cell material, transgenic technologies that may improve tissue structure as well as in vivo engraftment, and vascularization concepts. We also touch on legal and economic aspects that have to be considered before engineered myocardium may eventually be applied in patients and discuss who may be a potential recipient.
心肌工程旨在提供功能性心肌，以修复患病心脏，并在体外模拟心脏发育、生理学和疾病。在过去10年中，已经建立了几种促成技术来创建功能性心肌。尽管目前所采用的技术都无法产生与天然心肌完全匹配的结果，但可以预期，在对目前已确立的组织工程概念进行微调之后，人类心脏肌肉等效物将变得可用。本综述提供了心肌工程现状及其在心脏再生中的应用的最新情况。我们讨论了干细胞的应用，包括自体细胞材料的获取、可能改善组织结构以及体内植入的转基因技术，以及血管化概念。我们还涉及了在工程化心肌最终应用于患者之前必须考虑的法律和经济方面，并讨论了谁可能是潜在的接受者。
